Clinical Trial Update: A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase I study to evaluate safety, tolerability, pharmacokinetics, and efficacy of YL211 in patients with advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• YL211

Snippet

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. | Conditions: Advanced Solid Tumors | Phase 1 | Status: RECRUITING